In Phase C, contributors will receive ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment until condition progression or even the individuals are not able to tolerate the study drugs. - Participant eaten grapefruit or grapefruit solutions within three times before the https://abbv-744safetyandsideeffe13578.blogsumer.com/31451263/abbv-744-in-combination-with-immunotherapy-an-overview